- Induction of ovulation & pregnancy:
- SC 250mcg one day following last dose of follicle stimulating agent
- Use only after adequate follicular development has been determined
- Hold treatment if there is excessive ovarian response
- Injection: 250mcg/0.5mL
Not to be used if it has any particle or discoloration
Human chorionic gonadotropin
It stimulates late follicular maturation and resumption of oocyte meiosis & initiates rupture of pre-ovulatory ovarian follicle promoting fertility
- Injection site reaction
- Elevated ALT
- GI disorders
- Abdominal pain
- Nausea and vomiting
- Ovarian cysts
- Ovarian hyperstimulation syndrome
- Hypersensitivity to components
- Primary ovarian failure
- Uncontrolled thyroid disease
- Uncontrolled adrenal dysfunction
- Organic intracranial lesion such as pituitary tumor
- Undiagnosed abnormal uterine bleeding
- Ovarian cyst or enlargement of undetermined origin
- Sex hormone dependent cancer
- Pregnancy
- Tranexamic acid increases thrombosis risk
Drug Status
| Availability | Prescription only |
| Pregnancy | Category X |
| Breastfeeding | Unknown |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Ovitrelle | 250mcg/0.5mL | Injection | 1’s | Merck Ltd | Merck Ltd |